| Today’s Big NewsMar 19, 2024 |
| By Annalee Armstrong,Gabrielle Masson If you’re feeling like the obesity pipeline filled up overnight, you’re not alone. A new analysis from IQVIA takes a look at the drugs in development. |
|
|
|
By Zoey Becker The CEO collected his highest total compensation package since his first year in the role in 2019. |
By Nick Paul Taylor AstraZeneca is adding to the explosion of interest in radiopharmaceuticals, inking a $2 billion buyout to meld Fusion Pharmaceuticals with its cancer unit. |
By Conor Hale Johnson & Johnson MedTech has tapped Nvidia to help deliver real-time analyses of surgical data with AI models that can be deployed on-site using edge computing. |
|
Wednesday, March 27, 2024 | 10am ET / 7am PTThere can be numerous challenges encountered during biopharmaceutical process development. Join usfor an important look at formulation development specifically. Featuring real-world examples, this insightful discussion will explore key challenges, as well as the latest techniques and solutions for effectively overcoming current obstacles. Register now. 
|
|
By Andrea Park GLP-1 drugs—which include blockbusters like Eli Lilly’s Mounjaro and Novo Nordisk’s Ozempic and Wegovy, and which are expected to supplant PD-1 inhibitors as the best-selling drug class by the end of this year—received an hour of free, overwhelmingly positive publicity on Monday night. |
By Fraiser Kansteiner This year marks Novo Nordisk’s 30th anniversary in China, and it could also be the year the company's red-hot weight loss injection Wegovy (semaglutide) wins approval in the populous East Asian nation that’s increasingly grappling with diseases such as obesity and diabetes. |
By Max Bayer Neuropsychiatry biotech Engrail has closed a $157 million series B, adding crucial capital to help pay for clinical trials. The round was co-led by F-Prime Capital, Forbion and Norwest Venture Partners. |
By Conor Hale The company’s Fast Track Diagnostics division mainly sells its PCR tests in Europe, including multiplex assays for respiratory infections, STDs and childhood colds. About 90 Luxembourg-based employees will be let go this year. |
By Angus Liu Did Novartis break U.S. antitrust laws in the storied Eylea-Lucentis rivalry? Thanks to an appeals court ruling, Regeneron has another chance to lay out its argument. |
By James Waldron Bayer's hot flash drug elinzanetant has struck phase 3 gold again by relieving vasomotor symptoms, setting up the pharma to approach regulators about following Astellas’ Veozah to market. |
By Conor Hale The Silicon Valley-based Mendaera aims to put the telehealth portfolio to work supporting its image-guided, needle-based system. |
By Nick Paul Taylor The American Lung Association is sending “LUNG FORCE Heroes” to Washington, D.C. to ask Congress to loosen the purse strings and give federal agencies money that could lead to improved cancer outcomes. |
Fierce podcasts Don’t miss an episode |
| In this episode of 'The Top Line,' Fierce Biotech Senior Editor Annalee Armstrong interviews Karen Correa, Ph.D., from Takeda, discussing the crucial need for pharmaceutical companies to prioritize diversity in clinical trials. |
|
|---|
|
|
|
Monday, April 22, 2024 | 10am ET / 7am PTExplore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now! 
|
|
Whitepaper Explore the nuanced approaches necessary for successful pediatric drug development. Sponsored by: PPD |
Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
